These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21694627)

  • 1. Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers.
    Bernard K; Penelaud PF; Mocaër E; Donazzolo Y
    J Clin Psychopharmacol; 2011 Aug; 31(4):441-8. PubMed ID: 21694627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults.
    Makris AP; Rush CR; Frederich RC; Taylor AC; Kelly TH
    Exp Clin Psychopharmacol; 2007 Apr; 15(2):123-33. PubMed ID: 17469936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.
    Fabbrini M; Frittelli C; Bonanni E; Maestri M; Manca ML; Iudice A
    Clin Ther; 2005 Jan; 27(1):78-83. PubMed ID: 15763608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose of prednisone does not induce amphetamine-like subjective effects in healthy subjects.
    Warot D; Danjou P; Payan C; Rocher J; Brialy N; Puech AJ
    Therapie; 1995; 50(4):307-12. PubMed ID: 7482385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse liability assessment of atomoxetine in a drug-abusing population.
    Jasinski DR; Faries DE; Moore RJ; Schuh LM; Allen AJ
    Drug Alcohol Depend; 2008 May; 95(1-2):140-6. PubMed ID: 18328639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury.
    Lee H; Kim SW; Kim JM; Shin IS; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2005 Mar; 20(2):97-104. PubMed ID: 15641125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments.
    García-Gea C; Martínez-Colomer J; Antonijoan RM; Valiente R; Barbanoj MJ
    J Clin Psychopharmacol; 2008 Dec; 28(6):675-85. PubMed ID: 19011437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of caffeine in chewing gum on mood and attention.
    Smith A
    Hum Psychopharmacol; 2009 Apr; 24(3):239-47. PubMed ID: 19330801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential.
    Spencer TJ; Biederman J; Martin JM; Moorehead TM; Mirto T; Clarke A; Batchelder H; Faraone SV
    Postgrad Med; 2012 Jan; 124(1):166-73. PubMed ID: 22314126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 psychostimulants, modafinil and methylphenidate.
    Theunissen EL; Elvira Jde L; van den Bergh D; Ramaekers JG
    J Clin Psychopharmacol; 2009 Oct; 29(5):439-43. PubMed ID: 19745643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of a new central adrenergic agonist--modafinil--and D-amphetamine on sleep and early morning behaviour in young healthy volunteers.
    Saletu B; Frey R; Krupka M; Anderer P; Grünberger J; Barbanoj MJ
    Int J Clin Pharmacol Res; 1989; 9(3):183-95. PubMed ID: 2568348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer.
    Mulhern RK; Khan RB; Kaplan S; Helton S; Christensen R; Bonner M; Brown R; Xiong X; Wu S; Gururangan S; Reddick WE
    J Clin Oncol; 2004 Dec; 22(23):4795-803. PubMed ID: 15570081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of tianeptine in treating major recurrent unipolar depression. Study versus placebo for 16 1/2 months of treatment].
    Daléry J; Dagens-Lafant V; De Bodinat C
    Encephale; 1997; 23(1):56-64. PubMed ID: 9172969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.
    Schoedel KA; Stockis A; Sellers EM
    Epilepsy Behav; 2018 Jan; 78():194-201. PubMed ID: 29153631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.